LCT expands diabetes trial
Friday, 06 June, 2008
Living Cell Technologies (ASX: LCT) has decided to begin testing larger doses in its phase 1 clinical trial for type 1 diabetes.
In phase one of the trial, five patients were implanted with the lowest recommended dose of the company's DiabeCells, encapsulated insulin-producing cells sourced from pigs.
So far the patients have experienced no ill-effects, and have experienced a quantifiable reduction in the amount of insulin they require daily.
Both the number of patients and the dosage they receive has been doubled over the previous trial, with 10 patients receiving the double dose.
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
Low-dose drug prevents diabetes progression in young people
A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...
